Harald Weedon-Fekjær

Dr. Harald Weedon-Fekjær

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2006 in Demography
Verified
Journal Article
Open access
PDF file
GAGunnar Andersson
Gunnar Andersson
TNTurid Noack
Turid Noack
ASAne Seierstad
Ane Seierstad
HWHarald Weedon-Fekjær
Harald Weedon-Fekjær
The present study investigates the demographics of same-sex marriages—that is, registered partnerships—in Norway and Sweden. We give an overview of the demographic characteristics of the spouses of these partnerships, study patterns of their divorce risks, and compare the dynamics of same-sex couples with those of heterosexual marriages. We use longitudinal information from the population registers of the two countries that cover all persons in partnerships. Our demographic analyses include information on characteristics such as age, sex, geographic background, experience of previous opposite-sex marriage, parenthood, and educational attainment of the partners involved. The results show that in many respects, the distributions of married populations on these characteristics differ by the sex composition of the couples. Patterns in divorce risks are rather similar in same-sex and opposite-sex marriages, but divorce-risk levels are considerably higher in same-sex marriages. The divorce risk for female partnerships is double that for male partnerships.

17 June 2014 in BMJ
Verified
Journal Article
Open access
PDF file
HWHarald Weedon-Fekjær
Harald Weedon-Fekjær
PRP. R. Romundstad
P. R. Romundstad
LVLars J Vatten
Lars J Vatten
Objective To evaluate the effectiveness of contemporary mammography screening using individual information about screening history and breast cancer mortality from public screening programmes. Design Prospective cohort study of Norwegian women who were followed between 1986 and 2009. Within that period (1995-2005), a national mammography screening programme was gradually implemented, with biennial invitations sent to women aged 50-69 years. Participants All Norwegian women aged 50-79 between 1986 and 2009. Main outcome measures Multiple Poisson regression analysis was used to estimate breast cancer mortality rate ratios comparing women who were invited to screening (intention to screen) with women who were not invited, with a clear distinction between cases of breast cancer diagnosed before (without potential for screening effect) and after (with potential for screening effect) the first invitation for screening. We took competing causes of death into account by censoring women from further follow-up who died from other causes. Based on the observed mortality reduction combined with the all cause and breast cancer specific mortality in Norway in 2009, we used the CISNET (Cancer Intervention and Surveillance Modeling Network) Stanford simulation model to estimate how many women would need to be invited to biennial mammography screening in the age group 50-69 years to prevent one breast cancer death during their lifetime. Results During 15 193 034 person years of observation (1986-2009), deaths from breast cancer occurred in 1175 women with a diagnosis after being invited to screening and 8996 women who had not been invited before diagnosis. After adjustment for age, birth cohort, county of residence, and national trends in deaths from breast cancer, the mortality rate ratio associated with being invited to mammography screening was 0.72 (95% confidence interval 0.64 to 0.79). To prevent one death from breast cancer, 368 (95% confidence interval 266 to 508) women would need to be invited to screening. Conclusion Invitation to modern mammography screening may reduce deaths from breast cancer by about 28%.

1 December 2001 in Biometrics
Verified
Journal Article
Closed access
PDF file
OAOdd O. Aalen
Odd O. Aalen
ØBØrnulf Borgan
Ørnulf Borgan
HWHarald Weedon-Fekjær
Harald Weedon-Fekjær

8 February 2006 in Colorectal Disease
Verified
Journal Article
Closed access
PDF file
AWArne Wibe
Arne Wibe
ECE. Carlsen
E. Carlsen
ODO. Dahl
O. Dahl
KTK. M. Tveit
K. M. Tveit
HWHarald Weedon-Fekjær
Harald Weedon-Fekjær
TGThe Norwegian Rectal Cancer Group
The Norwegian Rectal Cancer Group

27 August 2004 in Biometrics
Verified
Journal Article
Closed access
PDF file
OAOdd O. Aalen
Odd O. Aalen
JFJohan Fosen
Johan Fosen
HWHarald Weedon-Fekjær
Harald Weedon-Fekjær
ØBØrnulf Borgan
Ørnulf Borgan
EHEinar Husebye
Einar Husebye

1 December 2005 in Journal of Medical Screening
Verified
Journal Article
Open access
HWHarald Weedon-Fekjær
Harald Weedon-Fekjær
LVLars J Vatten
Lars J Vatten
OAOdd O Aalen
Odd O Aalen
BLBo Lindqvist
Bo Lindqvist
STSteinar Tretli
Steinar Tretli
Objective: To assess if new screening techniques, increased use of hormone replacement therapy, or the transition from breast cancer screening trials to large scale screening programmes may influence the average time in preclinical screening detectable phase (mean sojourn time [MST]) or screening test sensitivity (STS). Setting: Screening and interval data for 395,188 women participating in the Norwegian Breast Cancer Screening Programme (NBCSP). Methods: Weighted non-linear least-square regression estimates using a tree step Markov chain model, and a sensitivity analysis of the possible impact by opportunistic screening between ordinary breast cancer screening rounds. Results: MST was estimated to 6.1 (95% confidence interval [CI] 5.1–7.0) years for women aged 50–59 years, and 7.9 (95% CI 6.0–7.9) years for those aged 60–69 years. Correspondingly, STS was estimated to 58% (95% CI 52–64 %) and 73 % (67–78 %), respectively. Simulations revealed that opportunistic screening may give a moderate estimation bias towards higher MST and lower STS. Assuming a probable 21% higher background incidence, due to increased hormone replacement therapy use, MST estimates decreased to 3.9 and 5.0 years for the two age groups, and STS increased to 75 and 85%. Conclusions: The new estimates indicate that screening detectable phase is longer than that found in previous mammography trials/programmes, but also that the sensitivity of the screening test is lower. Overall, the NBCSP detects more cancer cases than most previous trials/programmes.